Update date
30 Jun 2025
Shareable Research Card
SYRE - Spyre Therapeutics, Inc. Entity Public Float
This metric view shows SYRE - Spyre Therapeutics, Inc. entity public float history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q2 2025
- Latest reported value
- $1,100,000,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Jun 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q2 2025.
- Latest reported value on this page: $1,100,000,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Entity Public Float
Latest reported entity public float: $1,100,000,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q2 2025
SEC-backed company facts were refreshed from filings filed on 10 Apr 2026.
Benchmark Context
How Entity Public Float compares with peers
Spyre Therapeutics, Inc. is outside the visible top 120 companies for entity public float in the current sample.
Compared with
Compared with 120 companies reporting entity public float in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Entity Public Float is roughly flat versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Jun 2021 to 31 Dec 2025.
- Nearby companies in this sample: Seaport Global Acquisition II Corp. and NVIDIA CORP.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Spyre Therapeutics, Inc.: Entity Public Float
Latest period: Q2 2025. Period end: 30 Jun 2025. Units: USD. Frequency: quarterly.
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
Metric Snapshot
- Latest value
- $1,100,000,000
- Coverage range
- 30 Jun 2016 - 30 Jun 2025
- Fact rows
- 10
What This Metric Tells You
- Shows the reported level of entity public float over 30 Jun 2016 - 30 Jun 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 10 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Entity Public Float levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Seaport Global Acquisition II Corp. | $143,318,750,000,000 | Instant - 30 Jun 2022 | Open Seaport Global Acquisition II Corp. Entity Public Float |
| 2 | NVIDIA CORP (nvda) | $4,000,000,000,000 | Instant - 25 Jul 2025 | Open NVIDIA CORP Entity Public Float |
| 3 | Apple Inc. (aapl) | $3,253,431,000,000 | Instant - 28 Mar 2025 | Open Apple Inc. Entity Public Float |
| 4 | MICROSOFT CORP (msft) | $3,100,000,000,000 | Instant - 31 Dec 2024 | Open MICROSOFT CORP Entity Public Float |
| 5 | RenX Enterprises Corp. (renx) | $2,290,409,000,000 | Instant - 30 Jun 2025 | Open RenX Enterprises Corp. Entity Public Float |
| 6 | AMAZON COM INC (amzn) | $2,118,061,430,046 | Instant - 30 Jun 2025 | Open AMAZON COM INC Entity Public Float |
Metric Details
- Metric
- Entity Public Float (EntityPublicFloat)
- Taxonomy
- dei
- Units tracked
- USD
- Frequency coverage
- quarterly
- History range
- 30 Jun 2016 - 30 Jun 2025
- Facts on this page
- 10
- Description
- The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Entity Public Float, Quarterly (USD)
Entity Public Float, YoY Quarterly Change (%)
Spyre Therapeutics, Inc. Quarterly Entity Public Float (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | $1,100,000,000 | $0 | 0% | 30 Jun 2025 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q2 2024 | $1,100,000,000 | +$1,073,800,000 | +4098% | 30 Jun 2024 | 10-K | 27 Feb 2025 | 2024 | FY |
| Q2 2023 | $26,200,000 | -$4,100,000 | -14% | 30 Jun 2023 | 10-K/A | 18 Nov 2024 | 2023 | FY |
| Q2 2022 | $30,300,000 | -$307,100,000 | -91% | 30 Jun 2022 | 10-K | 02 Mar 2023 | 2022 | FY |
| Q2 2021 | $337,400,000 | -$48,600,000 | -13% | 30 Jun 2021 | 10-K | 08 Mar 2022 | 2021 | FY |
| Q2 2020 | $386,000,000 | +$208,300,000 | +117% | 30 Jun 2020 | 10-K | 18 Mar 2021 | 2020 | FY |
| Q2 2019 | $177,700,000 | -$21,400,000 | -11% | 30 Jun 2019 | 10-K | 24 Feb 2020 | 2019 | FY |
| Q2 2018 | $199,100,000 | +$148,500,000 | +293% | 30 Jun 2018 | 10-K | 07 Mar 2019 | 2018 | FY |
| Q2 2017 | $50,600,000 | +$26,000,000 | +106% | 30 Jun 2017 | 10-K | 13 Mar 2018 | 2017 | FY |
| Q2 2016 | $24,600,000 | 30 Jun 2016 | 10-K | 23 Mar 2017 | 2016 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.